CTLA4 and cancer: Since the first checkpoint inhibitor, ipilimumab, which targets CTLA-4, gained FDA approval, immunotherapy, especially anti-PD-1 and anti-PD-L1 antibody therapies, has shown inspiring clinical activity in various types of cancers and has become the new standard of anti-cancer therapy [27].